Relationship Between Metabolic and Histological Responses in People With Metabolic Dysfunction- Associated Steatohepatitis With and Without Type 2 Diabetes: Participant-Level Exploratory Analysis of the SYNERGY-NASH Trial With Tirzepatide

What Was Tested

Researchers studied Tirzepatide in this randomized controlled trial publication.

To explore the relationship between metabolic and histological responses in a phase 2 trial of tirzepatide in metabolic dysfunction-associated steatohepatitis (MASH).

Who Took Part

According to the abstract, 154 participants were involved.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

This is a participant-level post hoc analysis of the 52-week, double-blind, randomized, placebo-controlled SYNERGY-NASH trial (NCT04166773).

Metabolic changes were evaluated in responders and nonresponders for histological end points in 154 participants who completed the study on treatment.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

The participants were allocated by chance, so the Tirzepatide group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on Tirzepatide, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Tirzepatide group a baseline to be compared against.

The primary end point was MASH resolution without worsening of fibrosis.

What Was Measured

Topics PubMed links to this paper include Diabetes Mellitus, Type 2, Non-alcoholic Fatty Liver Disease, Liver Cirrhosis and Tirzepatide.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Tirzepatide in 154 participants.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2025 (Diabetes care), a journal based in United States.

More context: the Tirzepatide compound page, all human trials.